ArticlePharmaceutics2020
In-Depth Characterization of EpiIntestinal Microtissue as a Model for Intestinal Drug Absorption and Metabolism in Human.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™).Clinical pharmacology and therapeutics · 2025Article
- Human Small Intestinal Tissue Models to Assess Barrier Permeability: Comparative Analysis of Caco-2 Cells, Jejunal and Duodenal Enteroid-Derived Cells, and EpiIntestinalBioengineering (Basel, Switzerland) · 2025Article
- High-throughput assay for predicting diarrhea risk using a 2D human intestinal stem cell-derived model.Toxicology in vitro : an international journal published in association with BIBRA · 2025Article
- Qualification of the human Reconstructed Intestine Micronuclei Cytome assay for site-of-contact genotoxic hazard identification.NAM journal · 2025Article
- Inflammation-targeted delivery of Urolithin A mitigates chemical- and immune checkpoint inhibitor-induced colitis.Journal of nanobiotechnology · 2024Article
- Transport of perfluoroalkyl substances across human induced pluripotent stem cell-derived intestinal epithelial cells in comparison with primary human intestinal epithelial cells and Caco-2 cells.Archives of toxicology · 2024Article
- High-Throughput Assay for Predicting Diarrhea Risk Using a 2D Human Intestinal Stem Cell-Derived Model.bioRxiv : the preprint server for biology · 2024Article
- Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- Recent Advances in the Gastrointestinal Complex in Vitro Model for ADME Studies.Pharmaceutics · 2023Review
- Reconstructed human intestinal comet assay, a possible alternative in vitro model for genotoxicity assessment.Mutagenesis · 2023Article
- The Transport and Uptake of Resveratrol Mediated via Glucose Transporter 1 and Its Antioxidant Effect in Caco-2 Cells.Molecules (Basel, Switzerland) · 2023Article
- Challenges and Opportunities in the Oral Delivery of Recombinant Biologics.Pharmaceutics · 2023Review
- Isolation and Characterization of Distinct Rotavirus A in Bat and Rodent Hosts.Journal of virology · 2023Article
- Cell Cultures at the Air-Liquid Interface and Their Application in Cancer Research.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Urolithin A attenuates arsenic-induced gut barrier dysfunction.Archives of toxicology · 2022Article
- Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review.Archives of toxicology · 2022Review
- Congeners-Specific Intestinal Absorption Of Microcystins In AnFrontiers in toxicology · 2022Article
- The Inhibitory Activity of Curcumin on P-Glycoprotein and Its Uptake by and Efflux from LS180 Cells Is Not Affected by Its Galenic Formulation.Antioxidants (Basel, Switzerland) · 2021Article
- Monolayer platform using human biopsy-derived duodenal organoids for pharmaceutical research.Molecular therapy. Methods & clinical development · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Caco-2 model is a well-accepted in vitro model for the estimation of fraction absorbed in human intestine. Due to the lack of cytochrome P450 3A4 (CYP3A4) activities, Caco-2 model is not suitable for the investigation of intestinal first-pass metabolism. The purpose of this study is to evaluate a new human intestine model, EpiIntestinal microtissues, as a tool for the prediction of oral absorption and metabolism of drugs in human intestine. The activities of relevant drug transporters and drug metabolizing enzymes, including MDR1 P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), CYP3A4, CYP2J2, UDP-glucuronosyltransferases (UGT), carboxylesterases (CES), etc., were detected in functional assays with selective substrates and inhibitors. Compared to Caco-2, EpiIntestinal microtissues proved to be a more holistic model for the investigation of drug absorption and metabolism in human gastrointestinal tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.